Thu0196 tofacitinib in Patients With Rheumatoid Arthritis and Indicative of Depression and/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

Citera, Gustavo; Jain, Rakesh K.; Irazoque-Palazuelos, Fedra; Guzmán, Renato; Madariaga, H.; Gruben, David; Wang, L.; Stockert, Lori; Hsu, Ming‐Ann; Santana, Karina Talita de Oliveira; Ebrahim, Ahmed Husain; León, Darío Ponce de

doi:10.1136/annrheumdis-2020-eular.417

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the proportion of tofacitinib-treated patients who identified as having probable co-morbid major depressive disorder/anxiety (based on 36-item Short Form Health Survey [SF-36] mental component summary [MCS] score ⩽38) decreased from baseline with tofacitinib therapy (60% reduction after 6 months). 51 This analysis was limited by the use of the SF-36 MCS score to identify probable rather than confirmed major depressive disorder/anxiety. Further research using a gold-standard psychiatric interview is required to validate the use of SF-36 MCS score ⩽38.…”

Section: Use Of Tofacitinib Based On a Patient’s Baseline Characteris...mentioning

confidence: 99%

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Mortezavi

Mysler²

2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Tofacitinib was the first Janus kinase inhibitor to be approved for the treatment of rheumatoid arthritis (RA), and there is a large body of data to inform the efficacy and safety of this drug for patients at different places in their treatment journeys and with diverse demographics and characteristics. Here, we summarize tofacitinib clinical efficacy and safety data from some clinical trials, post hoc analyses, and real-world studies, which provide evidence of the efficacy of tofacitinib in treating patients with RA at various stages of their treatment journeys, and with differentiating baseline characteristics, such as age, gender, race, and body mass index. In addition, we review the safety data available from different patient subpopulations in the tofacitinib clinical development program, real-world data, and findings from the ORAL Surveillance post-marketing safety study that included patients aged ⩾50 years with pre-existing cardiovascular risk factors. The available efficacy and safety data in these subpopulations can enable better discussions between clinicians and patients to guide informed decision-making and individualized patient care.

show abstract

Section: Use Of Tofacitinib Based On a Patient’s Baseline Characteris...mentioning

confidence: 99%

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Mortezavi

Mysler²

2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Насонов

Авдеева²,

Лила

2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Расшифровка механизмов патогенеза иммуновоспалительных ревматических заболеваний (ИВРЗ), основными формами кото-рых являются ревматоидный артрит (РА), спондилоартриты (СпА), включающие анкилозирующий спондилит (АС) и псориатиче-П р о г р е с с в р е в м а т о л о г и и в X X I в е к е Насонов Е.Л.научный руководитель ФГБНУ «НИИР им. В.А. Насоновой», академик РАН, профессор, докт. мед. наук 1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»,

show abstract

Depression in Rheumatoid Arthritis: A Narrative Review—Diagnostic Challenges, Pathogenic Mechanisms and Effects

et al. 2022

View full text Add to dashboard Cite

Depression is one of the most frequent comorbidities in rheumatoid arthritis (RA); it takes an important toll on the quality of life of these patients and also leads to a decrease in life expectancy. The current article is a narrative review on depression in RA, with the objective to emphasize and raise awareness on the high prevalence, pathogenic mechanisms, and effects that depression has on RA patients. In RA, the prevalence of depression has been shown to be 2 to 3 times higher than in the general population, with a meta-analysis reporting that 16.8% of RA patients have a major depressive disorder. Future studies are needed to determine the most accurate self-reported depression questionnaires and their ideal threshold for defining depression as compared to diagnostic interview as gold-standard for patients with RA to allow better comparisons across studies. The pathogenesis of depression remains to be fully understood, but recent specialty literature suggests that immune-mediated processes are involved and that there are similarities between the neural networks recruited in inflammation and those implicated in the pathophysiology of depression. Depression in patients with RA is associated with poor long-term outcomes. Multiple studies have shown that depression in RA is associated with increased pain, fatigue, and physical disability. It alters treatment compliance, causes more comorbidities, and leads to higher mortality, partly through increased suicide risk. Depression in RA also increases health service utilization and healthcare costs directly through hospitalization, but also indirectly through loss of work productivity. Assessing depression could be a significant psychomarker of rheumatological outcome in RA.

show abstract

Thu0196 tofacitinib in Patients With Rheumatoid Arthritis and Indicative of Depression and/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials

Cited by 3 publications

References 0 publications

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Depression in Rheumatoid Arthritis: A Narrative Review—Diagnostic Challenges, Pathogenic Mechanisms and Effects

Contact Info

Product

Resources

About